Skip to main content
. Author manuscript; available in PMC: 2023 May 15.
Published in final edited form as: Expert Rev Anticancer Ther. 2022 Sep 19;22(10):1017–1027. doi: 10.1080/14737140.2022.2124971

Table 1.

Summary of Clinical Trials

Trial Phase Study Interventions Study Size References
NCT01211262 I/II IMCgp100 weekly IV fixed dosing (Arm 1) vs. IMCgp100 daily IV dosing (Arm 2) N = 84 [46]
NCT02570308 I/II Three-week step-up dosing regimen with 20 mcg for week 1, 30 mcg for week 2, then dose escalation for week 3, with 68 mcg as the identified R2PD for week 3 N = 42 (Phase I)
N = 127 (Phase II)		 [44,51]
NCT03070392 III Tebentafusp (20 mcg D1, 30 mcg D8, 68 mcg thereafter) vs. Investigator’s choice systemic therapy N = 378; Tebentafusp (N = 252) vs. Placebo (N = 126) [53]